The short answer
Melatonin and clozapine can each cause drowsiness, so additional sleepiness is a reasonable concern. The evidence reviewed does not establish how much melatonin increases sedation specifically with clozapine. Ask the prescribing team about the exact product and report troublesome daytime drowsiness.
What this answer covers
Oral melatonin with oral clozapine. The clearest official melatonin information concerns a 2 mg prolonged-release medicine; effects cannot be assumed identical across doses and formulations.
- Supplement or preparation
- Melatonin
- Medication ingredient
- clozapine
Why sleepiness is the concern
Clozapine can impair alertness and movement, and melatonin may also cause drowsiness. Together, they could make daytime alertness more difficult. This is an indirect precaution based on their known effects; it is not a measured estimate of how often extra sedation occurs with this exact combination.
What melatonin studies can tell us
An eight-week study in 44 people taking second-generation antipsychotics compared melatonin 5 mg with placebo. Some metabolic outcomes improved and no adverse events were reported. The inspected abstract did not provide a separate clozapine result. Benefits for weight or blood pressure do not establish whether melatonin increases sedation with clozapine.
Product and other medicines matter
The official melatonin label reviewed here covers a prolonged-release prescription product. It describes added impairment with some other sedating medicines, but those studies did not use clozapine. The melatonin formulation, dose and other medicines should be part of a prescribing review rather than assumed to have identical effects.
Pay attention to daytime alertness
Avoid driving or hazardous work if you feel drowsy or impaired, and tell the prescribing team if sleepiness interferes with normal activities. The sources do not establish a clozapine-specific melatonin dose, a mandatory dose gap or a reason to change clozapine yourself. Limited direct research does not prove that the combination is safe for everyone.
Evidence and practical considerations
Side effects & toxicity
Additional drowsiness is a plausible precaution when melatonin is added to clozapine; a pair-specific increase in sedation or severe CNS depression is not established.
- Exact scope
- Oral melatonin; prolonged-release product labeling provides indirect support. with Oral clozapine treatment, RxNorm 2626 IN.
- Medication form and route
- oral clozapine; oral melatonin
What remains uncertain
- Individual sedative effects and interactions with different medicines do not quantify the clozapine pair.
Factors that may matter: other sedating medicines; melatonin dose and formulation; baseline daytime drowsiness.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed clozapine.
Clozapine can cause sedation and impaired motor performance. Tobacco smoke induces CYP1A2; stopping inducers can raise clozapine levels. CYP1A2 inhibitors may raise levels.
How this applies: Medication-specific metabolism and sedation context; not a direct trial of these supplement pairs.
Does not specifically name cannabis, cannabidiol or melatonin. Class precautions require preparation-specific interpretation.
Source 2: product label
medicines.org.uk · Source check Sep 10, 2026
Population: Patients using prolonged-release melatonin; adult interaction studies.
May cause drowsiness; studies with zolpidem and thioridazine found additional impairment or subjective effects. Clozapine is not specifically studied.
How this applies: Supports an indirect drowsiness precaution, without substituting another antipsychotic for clozapine.
Specific formulation and other medicines; no direct clozapine interaction magnitude or respiratory-depression risk.
Research assessment: · Open full citations ↗
Physiologic interactions
A small mixed-antipsychotic trial reported metabolic benefits and no adverse events, but it cannot determine clozapine-specific benefit or sedation risk.
- Exact scope
- Melatonin 5 mg in a mixed-antipsychotic trial. with Oral clozapine treatment, RxNorm 2626 IN.
- Medication form and route
- oral clozapine; oral melatonin
What remains uncertain
- No clozapine-specific result in the inspected abstract; eight-week follow-up and small sample.
Read the supporting source summaries
Source 1: randomized placebo-controlled metabolic trial
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 44 analyzed patients with schizophrenia or bipolar disorder taking second-generation antipsychotics.
Some metabolic measures improved; stronger subgroup effects were in bipolar disorder rather than schizophrenia. No adverse events were reported.
How this applies: Context for adjunct research and a null adverse-event signal, not direct proof for the clozapine pair.
Abstract does not identify a clozapine-specific subgroup or quantify sedation. Metabolic outcomes cannot establish interaction safety.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Evidence and preparation-specific limitations assessed. | |
| Research summary published |
Article revision: fca088f079cf2671
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.